CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions
CDT Equity announced that its lead asset AZD5904, licensed from AstraZeneca, has advanced into the Patent Cooperation Treaty phase to secure global intellectual property protection. The drug demonstrated a favorable safety profile with 181 subjects dosed across five Phase 1 studies, targeting idiopathic male infertility and oncology-associated infertility.
Key figures
- Drug Name
- AZD5904
- Phase Of Trial
- Phase 1
- Subjects dosed
- 181
- Number of studies
- 5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.